NASDAQ:FENCFennec Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$8.06MA: $8.69▼$9.3952-Week Range N/AVolume750,635 shsAverage Volume335,476 shsMarket Capitalization$228.46 millionP/E RatioN/ADividend YieldN/ABeta0.25 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Fennec Pharmaceuticals has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesFennec Pharmaceuticals has received 160 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFennec Pharmaceuticals has received 167 “underperform” votes. (Add your “underperform” vote.)Community SentimentFennec Pharmaceuticals has received 51.07% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote “Outperform” if you believe FENC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.61% of the stock of Fennec Pharmaceuticals is held by insiders.Percentage Held by Institutions37.33% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to decrease by -68.80% in the coming year, from $1.25 to $0.39 per share. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FENC Previous Symbol CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.64) Net Income$-12,770,000.00 Net MarginsN/A Return on Equity-119.62% Return on Assets-104.57%Miscellaneous EmployeesN/A Outstanding Shares25,360,000Market Cap$228.46 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable 30 days | 90 days | 365 days | Advanced Chart Receive FENC News and Ratings via Email Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Fennec Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fennec Pharmaceuticals. When is Fennec Pharmaceuticals' next earnings date? Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Fennec Pharmaceuticals. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.03. View Fennec Pharmaceuticals' earnings history. What price target have analysts set for FENC? 3 brokers have issued 12 month price targets for Fennec Pharmaceuticals' stock. Their forecasts range from $15.00 to $18.00. On average, they anticipate Fennec Pharmaceuticals' stock price to reach $17.00 in the next year. View analysts' price targets for Fennec Pharmaceuticals. Has Fennec Pharmaceuticals been receiving favorable news coverage? News stories about FENC stock have been trending very positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Fennec Pharmaceuticals. Are investors shorting Fennec Pharmaceuticals? Fennec Pharmaceuticals saw a decrease in short interest in July. As of July 31st, there was short interest totaling 1,220,000 shares, a decrease of 10.3% from the July 15th total of 1,360,000 shares. Based on an average daily trading volume, of 256,600 shares, the days-to-cover ratio is presently 4.8 days. Currently, 5.7% of the company's stock are sold short. View Fennec Pharmaceuticals' Short Interest. Who are some of Fennec Pharmaceuticals' key competitors? Some companies that are related to Fennec Pharmaceuticals include Poseida Therapeutics (PSTX), BioCryst Pharmaceuticals (BCRX), Cellectis (CLLS), Vericel (VCEL), Passage Bio (PASG), Autolus Therapeutics (AUTL), Krystal Biotech (KRYS), Oyster Point Pharma (OYST), Osiris Therapeutics (OSIR), Avrobio (AVRO), Agenus (AGEN), Aerie Pharmaceuticals (AERI), Proteon Therapeutics (PRTO), Fusion Pharmaceuticals (FUSN) and Prevail Therapeutics (PRVL). View all competitors. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), Amarin (AMRN), Coherus Biosciences (CHRS), Fate Therapeutics (FATE), Aimmune Therapeutics (AIMT), Denali Therapeutics (DNLI), Karyopharm Therapeutics (KPTI), Obseva (OBSV), Allena Pharmaceuticals (ALNA) and Gilead Sciences (GILD). Who are Fennec Pharmaceuticals' key executives? Fennec Pharmaceuticals' management team includes the following people: Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)Mr. Robert C. Andrade, Chief Financial Officer (Age 43)Mr. Mark Gowland, ControllerMr. Lei Fang, Pres of Pharstat IncMs. Anne McKay, Regulatory Consultant (Age 64) What is Fennec Pharmaceuticals' stock symbol? Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC." Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Cadence Capital Management LLC (0.61%), Hartford Financial Management Inc. (0.20%), Wedbush Securities Inc. (0.13%), New York State Common Retirement Fund (0.08%), Strs Ohio (0.06%) and SG Americas Securities LLC (0.05%). View institutional ownership trends for Fennec Pharmaceuticals. Which major investors are buying Fennec Pharmaceuticals stock? FENC stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Strs Ohio, SG Americas Securities LLC, Wedbush Securities Inc., Hartford Financial Management Inc., UBS Group AG, and Cadence Capital Management LLC. View insider buying and selling activity for Fennec Pharmaceuticals. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How big of a company is Fennec Pharmaceuticals? Fennec Pharmaceuticals has a market capitalization of $0.00. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. What is Fennec Pharmaceuticals' official website? The official website for Fennec Pharmaceuticals is www.fennecpharma.com. How can I contact Fennec Pharmaceuticals? Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530. This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
